AI is poised to make a major impact on the life sciences industry. And regulatory oversight of AI use will, too. Follow critical FDA administrative activity with the FDA Artificial Intelligence (AI) Regulatory Activity Tracker in Practical Guidance Life Sciences. https://bit.ly/4eY3DB6
LexisNexis Practical Guidance’s Post
More Relevant Posts
-
AI is poised to make a major impact on the life sciences industry. And regulatory oversight of AI use will, too. Follow critical FDA administrative activity with the FDA Artificial Intelligence (AI) Regulatory Activity Tracker in LexisNexis Practical Guidance Life Sciences. https://bit.ly/4eY3DB6
To view or add a comment, sign in
-
-
Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants. #triageGO
Currently, more than 850 artificial intelligence enabled products have received FDA-authorization, yet recent cultural noise surrounding AI has caused controversy and unease. Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants.
To view or add a comment, sign in
-
Currently, more than 850 artificial intelligence enabled products have received FDA-authorization, yet recent cultural noise surrounding AI has caused controversy and unease. Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants.
AI & CDS Regulatory History and FDA Tools | Beckman Coulter Diagnostics
app.livestorm.co
To view or add a comment, sign in
-
Are you curious about how the FDA is regulating AI tools? We are frequently asked this when talking about our solutions, and we see a lot of confusion on the topic, especially when it comes to startups or companies new to the medical field. We are committed to not only deliver clinically proven solutions, but also to do so while being 100% compliant with FDA guidelines. Listen in to find out more!
Currently, more than 850 artificial intelligence enabled products have received FDA-authorization, yet recent cultural noise surrounding AI has caused controversy and unease. Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants.
AI & CDS Regulatory History and FDA Tools | Beckman Coulter Diagnostics
app.livestorm.co
To view or add a comment, sign in
-
Partner at Axon Lawyers: life sciences | medical devices | IVDs | medicines | biotech | AI | REACH | Batteries | EU law | Dutch law | M&A | commercial contracts | due diligence | healthcare | (regulatory) litigation
The #AIAct was published in the EU Official Journal today so this regulatory train has now officially left the station and the implementation deadlines countdown has now started. Pro tip for #medicaldevices and #invitrodiagnostics manufacturers: don't be unprepared like Claude (although Claude does realize its importance), but be prepared. This regulation will seriously move goalposts for any #medicaldevice company that has devices that incorporate an AI system or are software comprising an AI system. Contact us for help! #artificialintelligence #AI #medtech #EUMDR #EUIVDR #genetictesting #moleculardiagnostics #SaMD https://lnkd.in/e96TaPcE
To view or add a comment, sign in
-
-
Navigating the evolving intersection of AI and life sciences/health? If you are it's important to be aware that the increasing role of AI in areas like drug discovery and diagnostics is bringing with it a number of complex issues. For example: Can an AI be an inventor? What about AI-related patent exclusion? In this article, Mark Pearce delves into those issues and other intellectual property challenges, ranging from AI-generated innovations to data protection. The sooner we all get to grips with these issues, the sooner the benefits of faster data analysis can be seized to create better, cost-effective patient solutions. #LifeSciences #ArtificialIntelligence #AI #IntellectualProperty #Health #Diagnostics
Intellectual property issues around use of AI in life sciences
share.postbeyond.com
To view or add a comment, sign in
-
Artificial intelligence (AI) is well suited to improving healthcare outcomes. Some companies are already starting to use AI to help advance drug discovery and development. AI is poised to deliver medical breakthroughs due to its ability to study far more information than any human could examine through its superior pattern recognition abilities. In fact, it's already happening. Read more here: https://lnkd.in/e8-HwR5a Learn amore about our Impairment Detection Solutions at Predictmedix.com.
To view or add a comment, sign in
-
-
Last week, we had a great webinar about Artificial Intelligence in french. Don't miss the opportunity to attend the same webinar in English to learn more about Artificial Intelligence. The webinar is presented by Thomas LOMMATZSCH, director BU Medical of AFNOR at 5.00 pm CET today. Artificial Intelligence (AI) is a topic we are talking about more and more and this has an impact on the medical device sector. So, it is important to be prepared as a PRRC and also to be familiar with the EU AI Act if you work for a manufacturer that includes AI in its devices. The webinar is open to all and free of charge. To register for the session in English on March 26th at 5.00 pm CET, click here: https://lnkd.in/ewXs2uhQ We look forward to seeing you. #MDR #IVDR #EUAIAct #ArtificialIntelligence #PRRC #medicaldevice #regulation #regulatoryaffairs #quality #europe
To view or add a comment, sign in
-
-
According to a new research report "AI report 2023" published by intellectual property firm Marks & Clerk, only 12 EPO patent applications were filed in the field of drug discovery in 2022. This result is completely unbelievable. According to the report, the number of AI-based patents filed in the medical field will be 2,771 in 2022, a fourfold increase from 2018. Incredibly, looking at the subsector, the number of applications for the use of AI in drug discovery continues to decline, reaching only 12 applications in 2022. Rather than interpreting this as a lack of new inventions or a shift in research and development trends, maybe the true explanation relates to long-term strategy, with inventors instead choosing to use patents to protect the fruits of their drug discovery platforms, whilst keeping the algorithms confidential. https://lnkd.in/ejAJHjei #drugdiscovery #AI
AI report 2023 | Marks & Clerk
marks-clerk.page
To view or add a comment, sign in
-
While generative artificial intelligence (AI) (gen AI) has much promise, the global AI regulatory environment could pose challenges for the life sciences industry. Clarity in the regulatory environment can help accelerate the AI journey and adoption across regions. Explore the regulatory environment of AI in six geographical jurisdictions #DeloitteGreece #impactthatmatters #pharma #GenAI #regulation https://lnkd.in/dBf27sbH
Gen AI in life sciences: Regulations and global clarity
www2.deloitte.com
To view or add a comment, sign in
More from this author
-
Leap Day, healthcare guidance, LLC operating agreements & more!
LexisNexis Practical Guidance 5mo -
Bankruptcy timelines, insurance defense guidance, and more PG resources
LexisNexis Practical Guidance 5mo -
Love Contracts, AI in the workplace, and more from Practical Guidance
LexisNexis Practical Guidance 5mo